ArticleJournal of nanobiotechnology2022
Anti-inflammatory and immunomodulatory effects of the extracellular vesicles derived from human umbilical cord mesenchymal stem cells on osteoarthritis via M2 macrophages.
Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 3 syntheses or guidelines pooled it, 219 citations in OpenAlex.
- Mesenchymal stromal cells-derived extracellular vesicles in cartilage regeneration: potential and limitations.Stem cell research & therapy · 2025Pooled it
- Targeting osteoarthritis with small extracellular vesicle therapy: potential and perspectives.Frontiers in bioengineering and biotechnology · 2025Pooled it
- Human umbilical cord mesenchymal stem cells promoting knee joint chondrogenesis for the treatment of knee osteoarthritis: a systematic review.Journal of orthopaedic surgery and research · 2023Pooled it
- From pathogenic to reparative: Context-Dependent function of extracellular vesicles in osteoarthritis.Bioactive materials · 2027Review
- Injectable microsphere-based delivery strategies for stem cells and their derivatives in tissue regeneration.Bioactive materials · 2026Review
- Immunity-and-matrix-regulatory cells promote hyaline-like cartilage repair in osteoarthritis.Bioactive materials · 2026Article
- The mechano-immune-vesicle regulatory circuit: a systems framework for bone homeostasis and regeneration.Bioactive materials · 2026Review
- Mitochondrial reprogramming of alveolar macrophages by umbilical cord mesenchymal stem cells restores immune homeostasis inMaterials today. Bio · 2026Article
- Characterization of Umbilical Cord Mesenchymal Stromal Cells Overexpressing Klotho and In Vitro Anti-Aging Efficacy of Their Derived Extracellular Vesicles.International journal of molecular sciences · 2026Article
- MSC-EVs in Cartilage Regeneration and Immunomodulation: Mechanisms and Therapeutic Prospects for Osteoarthritis, Rheumatoid Arthritis and Intervertebral Disc Degeneration.International journal of molecular sciences · 2026Review
- ROS-responsive injectable hydrogel enables controlled release of human adipose tissue-derived extracellular vesicles for multifaceted osteoarthritis therapy.Journal of nanobiotechnology · 2026Article
- Biomimetic Bone Marrow Monocyte Membrane-Fused Extracellular Vesicles for Targeted Therapy of Myocardial Infarction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Scalable Isolation of Human Umbilical Cord MSC-Derived Exosomes and Their Therapeutic Potential in Osteoarthritis.Bioengineering (Basel, Switzerland) · 2026Article
- SIRT6 enhances the therapeutic potential of extracellular vesicles in mitigating osteoarthritis in rat models.Stem cell research & therapy · 2026Article
- Sea Urchin-Inspired Immuno-Instructive Ionic Flow Drives MSCs-Macrophage Communication to Promote Bone Regeneration.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Mesenchymal Stem/Stromal Cell-Free Therapies: Challenges and Opportunities.Molecular biotechnology · 2026Review
- MiR-100-5p is involved in severe pneumonia in children by targeting MTOR.BMC immunology · 2026Article
- Progress in research on the association between mesenchymal stem cell senescence and knee osteoarthritis.Journal of orthopaedic surgery and research · 2026Review
- Mesenchymal stromal cells therapy for remodeling the joint microenvironment: mechanisms, nanotechnology-enhanced strategies, and translation prospects.Stem cell research & therapy · 2026Review
- Application of exosomes derived from mesenchymal stem cells in osteoarthritis.Journal of orthopaedic surgery and research · 2026Review
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Osteoarthritis (OA) is a degenerative illness that greatly impacts the life quality of patients. Currently, the therapeutic approaches for OA are very limited in clinical. The extracellular vesicles (EVs) derived from different mesenchymal stem cells displayed a prominent therapeutic effect on OA. But most EVs have limited resources and the risks of host rejection, immunological response, and etc. Human umbilical cord mesenchymal stem cells (hUCMSCs) hold the advantages of easy availability, minimal immune rejection, and excellent immunomodulatory effects, although hUCMSCs-EVs have seldom been applied in OA. Herein, we investigated the potential immunomodulatory and anti-inflammatory effects of hUCMSCs-EVs on the treatment of OA. In our results, the treatment of hUCMSCs-EVs promoted the polarization of M2-type macrophages and the expression of anti-inflammation-related cytokines (IL-10). Notably, the supernate of M2 macrophages induced by hUCMSCs-EVs inhibited the level of inflammation-associated factors in OA chondrocytes caused by IL-1β. Further, injection of hUCMSCs-EVs in the articular lumen ameliorated progression of OA and exerted chondroprotective potential based on the OA joint model created by the surgical transection of the anterior cruciate ligament (ACLT). In addition, we found five highly enriched miRNAs in hUCMSCs-EVs, including has-miR-122-5p, has-miR-148a-3p, has-miR-486-5p, has-miR-let-7a-5p, and has-miR-100-5p by High-throughput sequencing of miRNAs, with targeted genes mainly enriched in the PI3K-Akt signaling pathway. Furthermore, we also detected the protein abundance of hUCMSCs-EVs using liquidation chromatography with tandem quadrupole mass spectrometry (LC-MS/MS) analysis. Thus, our study indicates that hUCMSCs-EVs can alleviate cartilage degradation during the OA progression, mechanically may through delivering key proteins and modulating the PI3K-Akt signaling pathway mediated by miRNAs to promote polarization of M2 macrophage, exhibiting potent immunomodulatory potential. The current findings suggest that hUCMSCs-EVs might serve as a new reagent for the therapy of OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.